(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2019 (26.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/182506 A1

(51) International Patent Classification:
*A61K 31/4418* (2006.01) *A61K 31/277* (2006.01)
*A61K 45/06* (2006.01) *A61K 31/4439* (2006.01)
*A61K 31/12* (2006.01) *A61P 25/16* (2006.01)
*A61K 31/198* (2006.01) *A61P 25/14* (2006.01)

(21) International Application Number:
PCT/SE2019/050260

(22) International Filing Date:
22 March 2019 (22.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1850327-6 23 March 2018 (23.03.2018) SE

(71) Applicant: **LOBSOR PHARMACEUTICALS AKTIEBOLAG** [SE/SE]; Kolonivägen 16, -, 741 44 Knivsta (SE).

(72) Inventor: **BOLSÖY, Roger**; Kolonivägen 16, -, 741 44 Knivsta (SE).

(74) Agent: **BRANN AB**; Box 3690, -, 103 59 Stockholm (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*

(54) Title: CONTINUOUS ADMINISTRATION OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISORDERS




Figure 1.

(57) Abstract: A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI),and (iii) a COMT inhibitor where the composition is continuously administrated.

WO 2019/182506 A1